Articles tagged with Brain Cancer
Johanna Joyce, a leading tumor immunologist, has begun her two-year term as President of the European Association for Cancer Research. She will focus on strategic oversight, promoting broad scientific collaboration, dialogue, and training, while addressing issues such as gender disparities in science.
Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Researchers used tissue samples, pathology images, and clinical data from 672 patients to train AI models to classify meningioma subtypes and predict recurrence risk. The findings suggest that AI can help clinicians obtain more detailed tumor information without requiring advanced genetic testing.
Researchers used patient-derived xenograft (PDX) models to study deadly DNA loops in cancer cells. They found significant similarities between human tumor samples and PDX models, including consistent presence of extra copies of oncogenes. These findings suggest that ecDNA-positive tumor cells may drive tumor growth and recurrence.
Researchers developed a nanofiber drug delivery system that uses electrospun fiber membranes to deliver multiple drugs in concert, demonstrating improved efficacy against glioblastoma. The system enables localized long-term delivery of drugs directly at the tumor site after surgery.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
A new study reveals that nitrosylcobalamin, a vitamin B12 analog, selectively crosses the blood-brain barrier and targets glioblastoma tissue, demonstrating broad antitumor activity. The therapy also shows synergistic activity with existing treatments, offering a promising new strategy for treating this deadly brain cancer.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
Researchers have discovered that errors in the final step of cell division can cause dramatic changes in developing brain cells, leading to abnormalities such as multiple nuclei and cilia. The study found that a protein called p53 acts as a guardian of brain development by triggering the self-destruction of abnormal cells.
Researchers found that mouth stem cell proteins can slow down aggressive brain cancer growth, reduce tumour size and enhance chemotherapy effectiveness. The study suggests a new strategy to disrupt the body's defense systems against cancer.
A personalized vaccine has been shown to be safe and effective in treating glioblastoma, a fast-growing brain cancer. The vaccine elicited robust and broad immune responses that appeared to increase recurrence-free survival in patients after surgery.
Glioblastoma is a highly aggressive brain tumor that has seen modest improvements in survival rates over the past decade. Researchers at UCLA's Jonsson Comprehensive Cancer Center are part of a national effort to develop more personalized approaches to care, combining advanced imaging and analysis of tumor tissue samples and blood test...
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
Researchers at DZNE discovered complex, situation-dependent interactions between glioblastoma cells and microglia in the brain. The study found that microglial activity changes as tumors spread, influencing containment and spread of the disease.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Researchers have created a 3D experimental system to study the response of low-grade gliomas to drugs, providing a more realistic environment for testing treatments. The system uses organoids from pluripotent stem cells to replicate glioma development and characteristics.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
A study reveals CHKA and EGFR cooperate to activate the MAPK pathway, driving glioma progression. CHKA knockdown suppresses tumor growth, while EGFR overexpression rescues this effect.
A team of researchers has created a 3D model of pediatric brain tumors using biopsy-derived organoids, allowing for more accurate testing of new drugs. The model, which accurately reproduces the human environment, preserves the molecular characteristics of the original tumor and maintains cellular heterogeneity.
A recent study has revealed that brain tumors use a protein called MIF to reprogram immune cells, such as macrophages and microglia, to drive tumor growth. The researchers have identified a drug, ibudilast, which can block this process, slowing metastasis in animal models and fresh patient samples.
Researchers at Adelaide University identified CD47 as a critical mechanism driving glioblastoma growth and spread. The study found that removing or blocking CD47 reduced tumour cell proliferation, migration, and invasion, leading to improved survival times in animal models.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Recent discoveries have shed light on gene expression control in tumor growth, revealing the critical role of epigenetic marks and genomic imprinting. The findings have significant implications for cancer treatment, as they suggest that disrupting the tumor's access to neural signaling may halt its growth.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
A study by St. Jude Children's Research Hospital found that radiation therapy contributes to hearing loss in children treated for brain tumors, leading to greater cognitive decline. Children with severe hearing loss experienced a more significant decline in cognitive measures compared to those without.
PhD candidate Michael Gomes is developing advanced nanoscale drug carriers to deliver chemotherapy more effectively to brain tumours. His research focuses on polydopamine nanoparticles and the glymphatic system to reach tumours directly, potentially increasing drug concentrations and reducing toxic effects.
A new study published in Redox Biology found that an experimental neuroprotective drug called P7C3-A20 can prevent the negative side effects of whole brain radiotherapy, including memory problems and depression. The drug was shown to reduce oxidative stress and protect nerve cells in mice with WBRT-induced brain damage.
Researchers identified a previously unrecognized metabolic defence mechanism in aggressive brain tumours: a sugar-rich shield that protects tumour cells from ferroptosis. The study found that the sugar shield and lipid droplet storage mechanisms cooperate to evade cell death.
A single injection of an oncolytic virus recruits immune cells to penetrate and persist deep within brain tumors, inducing long-term infiltration of immune T cells. This therapy expands pre-existing T cells in the brain, leading to a therapeutic benefit for patients with glioblastoma.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
A UCalgary study found that adding high doses of vitamin B3 to the treatment plan may help rejuvenate compromised immune cells to kill tumour cells. The clinical trial showed promising results, with 82% of participants free of cancer progression at six-months.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer. They discovered a small molecule called miR-181d acts like a master switch that controls how much MGMT is produced by each glioblastoma cell.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.
Researchers developed miniature 3D tumor organoid models that closely mimic the human brain, revealing how glioblastoma interacts with surrounding brain cells and immune system. The models identified PTPRZ1 as a key regulator of tumor behavior, which helps determine its aggressiveness.
Cancer cells tap into the nervous system's power grid by forming synaptic contacts with nerve cells, promoting tumor growth and spread. Venkataramani's research aims to repurpose the drug perampanel for glioblastoma treatment and develop gene therapy approaches to disconnect tumors from the nervous system.
Researchers found that patients with circulating tumor DNA (ctDNA) positive after neoadjuvant therapy had a higher risk of disease recurrence, regardless of pathologic complete response. Patients who cleared ctDNA after treatment experienced improved recurrence-free survival.
Researchers developed a new method to identify effective treatment combinations for glioblastoma by analyzing individual cell types and their gene expression signatures. This approach has the potential to personalize cancer treatment and may be useful for other cancers and diseases.
Researchers developed a new diagnostic chip that can detect tumor cells in blood, allowing for real-time monitoring of brain cancer treatment effectiveness. The GlioExoChip uses extracellular vesicles to assess treatment response, providing a quick and minimally invasive way to inform doctors about chemotherapy efficacy.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
MIT chemists successfully synthesized verticillin A, a fungal compound that has shown potential as an anticancer agent. The researchers then generated derivatives of the compound and tested them against pediatric brain tumors, finding that some were effective against cancer cells with high levels of EZHIP protein.
A new combination treatment of eflornithine and lomustine has been shown to improve overall survival rates for patients with grade 3 astrocytoma by about 35 months compared to standard treatment. Patients with grade 4 IDH-mutant astrocytoma or glioblastoma did not benefit from the new therapy.
Christina Tringides' CHAMELEON project aims to develop soft, sensor-laden brain implants that can monitor and treat glioblastoma with greater precision. Her lab creates hydrogel-based arrays with conductive electrodes to track neural signals in real-time.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
A clinical trial found a nearly 40% increase in overall survival for glioblastoma patients treated with focused ultrasound and chemotherapy. The study also showed that liquid biopsy tests can detect cancer biomarkers, which are closely concordant with patient outcomes.